arrow
P

Penny L. Moore

national institute for communicable diseases of the national health laboratory service
H指数:59
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials

抗体介导预防试验中,使用广谱中和抗体VRC01进行预防性治疗会在感染后选择逃逸突变体

2026-09-280
OA
mRNA-1273 SARS-CoV-2 vaccination in people with HIV: an immune correlates analysis of CD4 + T cell responses in the multicenter CoVPN 3008 observational study

mRNA-1273 SARS-CoV-2疫苗接种在HIV感染者中的免疫相关分析:多中心CoVPN 3008观察性研究中CD4+ T细胞反应

2026-09-280
OAAI
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials

在抗体介导的预防试验中,广泛中和抗体VRC01对HIV突破性病毒人群的影响

2026-04-030
OAAI
Humoral and cellular immunogenicity of COVID-19 vaccine boosters in participants with advanced HIV disease
2026-01-070
OAAI
Safety and immunogenicity of DNA omicron booster Alveavax-v1.2 in Ad26.COV2.S-vaccinated adults

DNA奥密克戎加强针Alveavax-v1.2在Ad26.COV2.S疫苗接种成人中的安全性与免疫原性

2025-11-100
OAAI
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity

来自人类HIV-1疫苗试验参与者的糖链反应性抗体显示出广泛的病原体交叉反应性

2025-11-010
PRE
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy

HIV-1精英中和者队列的表征分析揭示了一种靶向CD4bs的广谱中和抗体,可用于HIV-1的预防和治疗

2025-10-060
OA
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV

中和抗体和结合抗体是CoVPN 3008研究中HIV感染者COVID-19风险的相关因素。

2025-10-060
OAAI
Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort study

非洲地区人群中SARS-CoV-2感染康复者的中和抗体应答随时间变化:一项队列研究

2025-09-110
OAAI
Africa is an Essential Partner in the Research and Development of an HIV Vaccine

非洲是HIV疫苗研究与开发的重要合作伙伴

2025-09-010
PRE
Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults

疟原虫恶性疟原虫寄生血症不会降低HIV感染者接种mRNA COVID-19加强疫苗后的中和抗体反应

2025-08-010
OAAI
Retaining African networks is urgent for global health

保持非洲网络对于全球健康至关重要

2025-07-310
OAAI
Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C

体液、T细胞和免疫基因表达对既往MIS-C的儿童小群体接种SARS-CoV-2疫苗后的反应

Vaccine
IF3.5
2025-07-060
PRE
Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine

莫桑比克队列中接种1剂或2剂BBIBP-CorV疫苗后的混合免疫

2025-06-150
OAAI
Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women

与固定剂量相比,基于体重的CAP256V2LS(一种用于女性HIV预防的广谱中和抗体)的群体药代动力学研究

2025-06-010
OAAI
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance
2025-02-250
OAAI